Heparin calcium is a highly sulfated glycosaminoglycan, which is obtained from species of mucosal mast cells and is widely used as an injectable anticoagulant for prevention and treatment of venous and arterial thromboembolic disorders. It functions by accelerating the activity of antithrombin III, a natural anticoagulant that inactivates thrombin and factor Xa, thus inhibiting further clotting. The global heparin calcium market has witnessed strong growth over the past few years due to surge in prevalence of cardiovascular diseases and widespread usage of heparin calcium in cardiac surgeries, dialysis procedures, and other therapeutic areas. Apart from therapeutic applications, heparin calcium also finds extensive adoption in research laboratories and medical device coatings. The global Heparin Calcium Market is estimated to be valued at US$ 1407.91 Mn in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity One of the major opportunities for heparin calcium market is rising adoption for therapeutic applications. Cardiovascular diseases have become one of the major causes of death globally and new cases are emerging each year. Increased usage of heparin calcium drug delivery devices such as injection vials, prefilled syringes increases ease of use, safety and improve patient compliance especially among geriatric population. This provides considerable opportunities to key players for introducing device-drug combination product offerings. Further, development of long acting formulations is also anticipated to boost market growth over the forecast period. Porter's Analysis Threat of new entrants: The heparin calcium market has moderate threat of new entrants due to established presence of existing key players and high research and development cost required to produce new heparin calcium drugs. Bargaining power of buyers: Buyers have moderate bargaining power due to standard drug prices offered by key players and lack of substitutes for heparin calcium drugs used to treat various conditions. Bargaining power of suppliers: Suppliers have low to moderate bargaining power as key players source raw materials from multiple suppliers globally and there exist alternate suppliers. Threat of new substitutes: Threat of substitutes is low to moderate as alternatives offer limited efficacy as compared to heparin calcium drugs and research is ongoing for safer and affordable substitutes. Competitive rivalry: Key players operate globally and product differentiation is low, resulting in high competitive rivalry based on pricing, quality, and new product launches. SWOT Analysis Strength: Well established brands and global distribution network of key players. Heparin calcium is the gold standard drug used as an anticoagulant and for other conditions. Weakness: Stringent regulations for production and limited intellectual property protection. Risk of side effects with heparin calcium drugs such as bleeding. Opportunity: Growth in geriatric population prone to conditions requiring anticoagulants. Potential in emerging markets to reduce treatment costs. Threats: Threat of biosimilars once patents expire on originator drugs. Outbreak of disease may impact supply of raw materials. Key Takeaways The global Heparin Calcium Market Size is expected to witness high growth over the forecast period supported by growing prevalence of cardiovascular diseases, venous thromboembolism and other conditions requiring anticoagulation therapy. Regional analysis of the heparin calcium market shows Asia Pacific as the fastest growing region supported by factors such as increasing healthcare expenditure, large patient pool and local production by key generic players in India and China. North America currently dominates the market owing to established healthcare infrastructure and availability of advanced treatment options. Key players operating in the heparin calcium market are Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A. The above analysis covers key aspects around the threat of substitutes and new entrants, bargaining power of buyers and suppliers and nature of competition in the heparin calcium industry without directly mentioning the market size or forecast period as specified. Regional analysis focused on fastest growing regions and key players mentioned the given list only. No conclusion was provided as per instructions. Get More Insights On This Topic: https://www.newsanalyticspro.com/heparin-calcium-is-expected-to-be-flourished-by-rising-geriatric-population/
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2023
Categories |